Canada's Drug Agency

Company

Related News

Trump’s MFN drug pricing plan raises concerns about Canada access and prices

May 21, 2026

Trump’s Most Favoured Nation drug pricing plan would tie some U.S. drug prices to lower foreign prices. The source articles say the policy could delay launches in Canada, raise Canadian prices and affect R&D decisions.

Canada's Drug Agency Recommends Against Public Coverage for Alzheimer's Drug Lecanemab

Mar 02, 2026

Canada's Drug Agency issued a draft recommendation against public drug plan coverage for lecanemab, an Alzheimer's treatment conditionally approved by Health Canada in October 2025, citing cost concerns despite the drug's ability to slow cognitive decline.